Advanced

Fine-tuning lung cancer nanotherapy using closed cardiopulmonary circulation

Bölükbas, D. A. LU ; Morrone, C. ; Doryab, A. ; Datz, S. ; Gößl, D. ; Meyer-Schwickerath, C. ; Vreka, M. ; van Rijt, S. H. ; Stöger, T. and Stathopoulos, G. T. , et al. (2019) 40.
Abstract


Statement of Purpose: Lung cancer is the leading cause of cancer-related deaths and efficient therapies remain elusive. One emerging approach is to use nanoparticles (NPs) that are designed to specifically target malignant cells (1). Such targeting increases on-site drug doses and reduces systemic side effects. A common target in lung tumors is epidermal growth factor receptor (EGFR). Here, we explored the targeting efficacy of EGFR-targeted mesoporous silica nanoparticles (MSN
GE11
) for lung cancer treatment. Though specifically taken up by... (More)


Statement of Purpose: Lung cancer is the leading cause of cancer-related deaths and efficient therapies remain elusive. One emerging approach is to use nanoparticles (NPs) that are designed to specifically target malignant cells (1). Such targeting increases on-site drug doses and reduces systemic side effects. A common target in lung tumors is epidermal growth factor receptor (EGFR). Here, we explored the targeting efficacy of EGFR-targeted mesoporous silica nanoparticles (MSN
GE11
) for lung cancer treatment. Though specifically taken up by cancer cells in vitro, when administered intravenously or intratracheally in lung cancer mouse models, the NPs could not reach the depths of solid tumors and often strayed away from their target. This raises concerns whether NPs are suitable for therapeutically targeting lung tumors and challenges translational value of current approaches. To circumvent physiological barriers of solid lung tumors and consequent systemic clearance of NPs, we extended our analysis to a treatment strategy where the NPs are administered intravenously in a closed cardiopulmonary (CP) circulation loop. This approach not only makes the therapy more local, but also eliminates confounding factors for NP delivery such as liver/spleen deposition of NPs in vivo.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
host publication
Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium : 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
volume
40
publisher
Swiss Society for Biomaterials
external identifiers
  • scopus:85065450925
ISBN
9781510883901
language
English
LU publication?
yes
id
5cd56f9d-6409-4759-8f6e-18bdf21b66d0
date added to LUP
2019-06-03 14:23:53
date last changed
2019-06-11 04:08:00
@inproceedings{5cd56f9d-6409-4759-8f6e-18bdf21b66d0,
  abstract     = {<p><br>
                                                         Statement of Purpose: Lung cancer is the leading cause of cancer-related deaths and efficient therapies remain elusive. One emerging approach is to use nanoparticles (NPs) that are designed to specifically target malignant cells (1). Such targeting increases on-site drug doses and reduces systemic side effects. A common target in lung tumors is epidermal growth factor receptor (EGFR). Here, we explored the targeting efficacy of EGFR-targeted mesoporous silica nanoparticles (MSN                             <br>
                            <sub>GE11</sub><br>
                                                         ) for lung cancer treatment. Though specifically taken up by cancer cells in vitro, when administered intravenously or intratracheally in lung cancer mouse models, the NPs could not reach the depths of solid tumors and often strayed away from their target. This raises concerns whether NPs are suitable for therapeutically targeting lung tumors and challenges translational value of current approaches. To circumvent physiological barriers of solid lung tumors and consequent systemic clearance of NPs, we extended our analysis to a treatment strategy where the NPs are administered intravenously in a closed cardiopulmonary (CP) circulation loop. This approach not only makes the therapy more local, but also eliminates confounding factors for NP delivery such as liver/spleen deposition of NPs in vivo.                         <br>
                        </p>},
  author       = {Bölükbas, D. A. and Morrone, C. and Doryab, A. and Datz, S. and Gößl, D. and Meyer-Schwickerath, C. and Vreka, M. and van Rijt, S. H. and Stöger, T. and Stathopoulos, G. T. and Lindstedt, S. and Bein, T. and Meiners, S. and Wagner, D. E.},
  booktitle    = {Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium : 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence},
  isbn         = {9781510883901},
  language     = {eng},
  publisher    = {Swiss Society for Biomaterials},
  title        = {Fine-tuning lung cancer nanotherapy using closed cardiopulmonary circulation},
  volume       = {40},
  year         = {2019},
}